Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the (Q58375437)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

Europe PubMed Central

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

based on heuristic

inferred from title

0 references

0 references

infectious disease

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Carl Fichtenbaum

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

3

object named as

Judith A Aberg

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Dennis Sprecher

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Michael P Dubé

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

John G Gerber

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Karen T Tashima

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

W Keith Henry

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Judith S Currier

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Marshall J Glesby

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Adult AIDS Clinical Trials Group Cardiovascular Subcommittee

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

HIV Medical Association of the Infectious Disease Society of America

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

0 references

publication date

15 August 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Clinical Infectious Diseases

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

37

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

613-627

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Ischemic cardiovascular disease in persons with human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Metabolic effects of indinavir in healthy HIV-seronegative men

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP).

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Management of dyslipidemia in adults with diabetes

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: Relation to indices of cytokine production

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Statin-fibrate combination therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Disorders of glucose metabolism in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Effect of a combination of gemfibrozil and niacin on lipid levels

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1086%2F378131

21 January 2018

Identifiers

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942391%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58375437&oldid=1796083980"